stockrow
Friday 6 November 2026
Export NEUP’s income statement to Excel — free account
Neuphoria Therapeutics Inc.
NEUP Healthcare Biotechnology
Neuphoria Therapeutics Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.2 million, down 92.5% from fiscal 2025.
- Revenue
- −107.3%
- EPS
- +83.6%
- Free cash flow
- +133.9%
Quarter to June 2026, against a year earlier
2.80
0.03
+1.08%
Follow NEUP
Alert me
Neuphoria Therapeutics Inc. (NEUP) P/E ratio
Neuphoria Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 5.4× (June 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2025 | 0.0× | — |
| Mar 2025 | 4.3× | — |
| Dec 2024 | 0.0× | — |
| Jun 2023 | 0.0× | — |
| 5 more quarters | Free account |
Against its own ten years
Low 0.0×
High 5.4×
Ten-year median
0.0×
Current reading's percentile
95
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NEUP Neuphoria Therapeutics Inc. | n/m |
| PLUR Pluri Inc. compare | n/m |
| MRKR MARKER THERAPEUTICS, INC. compare | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | n/m |
| ATYR aTyr Pharma, Inc. compare | n/m |
| VAXX Vaxxinity, Inc. compare | n/m |
| CTXR Citius Pharmaceuticals, Inc. compare | n/m |
| ABOS Acumen Pharmaceuticals, Inc. compare | n/m |
| KYNB Kyntra Bio Inc compare | 0.1× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)